| ￥2700 | |
| Z06800-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | ≥ 95% as analyzed by reducing SDS-PAGE | ||||
| Endotoxin Level | < 0.2 EU/μg of protein by gel clotting method | ||||
| Biological Activity | Immobilized Human BAFF/TNFSF13B/CD257, His at 1 μg/ml (100μl/well) on the plate can bind BCMA/TNFRSF17 hFc Chimera, Human (Cat.No.: Z06800). | ||||
| Theoretical Molecular Weight | 31.4 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation and dimerization, the protein migrates to 70 kDa based on SDS-PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS, pH7.2 | ||||
| Reconstitution | Reconstitute the lyophilized powder with deionized water (or equivalent) to a final concentration of 0.5 mg/ml. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of BCMA/TNFRSF17 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
BCMA/TNFRSF17 hFc Chimera, Human on SDS-PAGE under reducing and non-reducing conditions. The purity is greater than 95%. »
Immobilized BAFF/TNFSF13B/CD257[Biotin], His & Avi, Human (Cat. No.Z04413) at 1 μg/mL (100 μL/well) on the plate. Dose response curve for BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) with the EC50 of 1.62 ng/ml determined by ELISA. »
Immobilized BCMA/TNFRSF17 hFc Chimera, Human (Cat. No.Z06800) at 1 μg/mL (100 μL/well) can bind Anti-Human BCMA antibody. »
| Target Background | BCMA (B-cell maturation antigen), also called TNFRSF17, is encoded by the TNFRSF17 gene. It acts as a cell surface receptor of the TNF receptor superfamily. BCMA recognizes B-cell activating factor (BAFF). It interacts with the B-cell activating factor TNFSF13B. |
| Synonyms | CD269; TNFRSF17; BCMA; BCM; TNFRSF13A |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
